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duration was analyzed using Kaplan Meier estimates.
Statistical comparison of the survival curves was done
with the Log-rank test. We pooled IMS Mediplus data
(patient medical records completed by general practitio-
ners) from Germany, France and the United Kingdom for
analysis. Data was obtained for all irbesartan patients
with at least one year of follow-up and from randomly
selected samples of patients treated with either diuretics,
beta blockers, calcium channel blockers, ACE inhibitors,
or other AIIRA. Patients were newly diagnosed with hy-
pertension between October 1, 1997 and November 30,
1998 and initiated antihypertensive treatment as mono-
therapy.
RESULTS: Patients included (2,416) were initiated on di-
uretics (422), beta blockers (441), calcium channel block-
ers (466), ACE inhibitors (333), losartan (188), irbe-
sartan (380), other AIIRA (186). When irbesartan was
prescribed, more patients remained on that therapy
(60.8%) than with all other antihypertensives (44.2%, p 
0.001), or other AIIRAs (51.3%, p  0.009). Compared
to patients taking all other antihypertensives, fewer pa-
tients receiving irbesartan required adjunctive therapy
(16.1% vs 25.3%, p  0.001) or switched therapy (9.0%
vs 13.6%, p  0.013).
CONCLUSIONS: Irbesartan was superior compared to
all antihypertensives in achieving persistence of initial
therapy. By evaluating persistence rather than compli-
ance, we captured both the patient’s and the physician’s
role in determining the course of treatment.
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OBJECTIVE: Controlled clinical trials have demon-
strated the positive impact of statin therapy on health
outcomes in hyperlipidemic patients. The positive impact
of adherence is seemingly intuitive and many programs
have been designed to improve adherence. However,
there are few studies analyzing the cost-effectiveness of
medication-adherence interventions. This decision analy-
sis model will examine the cost-effectiveness of programs
designed to enhance medication adherence in patients
taking statins. The model varies the medication-adher-
ence rate and program costs to determine the differences
in the expected outcome of three different types of inter-
vention.
METHODS: Data from published clinical and pharma-
coeconomic studies were entered into a decision analysis
model. A Monte Carlo simulation using 10,000 trials
was used with beta distributions for the assumptive vari-
ables. The baseline adherence rate was set at 67% and
the cardiovascular event rate at 1.5%. Behavioral (B)
type interventions were assumed to increase adherence by
8.61%, Educational (E) interventions by 11.22% and
Combined (C) B and E by 17.04%. Program costs were
estimated as follows: B  $200, E  $100, and C 
$225 per patient. Cardiovascular and serious medication-
related events were also used as outcomes. The cost-per-
patient-per-event avoided was calculated. ANOVA was
used to test for differences among intervention types.
RESULTS: The results showed that the interventions in-
creased the number of events avoided in the first year by
0.04 (95% CI  0.04,0.12) for B, by 0.06 (95%CI 
0.02, 0.14) for E and by 0.08 (95%CI  0.02, 0.14)
for C. The cost-per-event-per-patient avoided in the first
year of treatment was B  $6,038, E  $2,568 and C 
$3,839. There was a statistical difference among all inter-
vention types with respect to cost of events avoided.
CONCLUSIONS: There was no difference in the number
of events avoided in the first year of statin treatment with
respect to intervention type. While C interventions yielded
more events avoided, E interventions appear to be the
most cost-effective. More study on the cost-effectiveness
of medication adherence programs is required.
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Patients with heart failure suffer from poor health out-
comes due to multiple co-morbidity requiring multiple
medications. Patients who misunderstand their diagnosis
and treatment plan may use their medication subopti-
mally. Providing knowledge through education is one
mechanism that can help patients improve medication
compliance.
OBJECTIVES: To develop and establish measurement
properties of two distinct instruments that can be used in
patients with heart failure (HF) to measure acceptability
of educational materials and subsequent knowledge
gained following an educational intervention.
METHODS: Using an expert panel, we developed mini-
mal criteria required to educate patients with HF. Subse-
quently, we developed and tested two questionnaires.
The first measure, which we refer to as a measure of edu-
cational material acceptability (EMA) was developed to
help us differentiate between booklets designed to edu-
cate patients with HF so as to select which booklets were
most acceptable to the patient. The second measure,
which we refer to as the measure of knowledge acquisi-
tion (MKA), was developed to help us evaluate the im-
pact of our educational intervention on knowledge. MKA
